Pharmacokinetics of Amcenestrant in Female Hepatic Impaired Participants as Compared to Participants With Normal Hepatic Function

Inclusion Criteria: For participants with hepatic impairment: * Participant must be 40 to 75 years of age, inclusive. * Female participants who are postmenopausal or are post-bilateral surgical oophorectomy not linked to a history of cancer. Menopause is defined as being amenorrheic for at least 12 months without an alternative medical cause, with plasma FSH level \>30 IU/L or age ≥60 years. * Stable chronic liver disease assessed by medical history, physical examination, laboratory values * Body weight within the range 50 kg (40 kg for site in South Korea) to 110 kg and body mass index (BMI) within the range 18 to 36 kg/m2, inclusive. * For moderate hepatic impairment cohort: Child-Pugh total score ranging from 7 to 9, inclusive. * For mild hepatic impairment cohort: Child-Pugh total score ranging from 5 to 6, inclusive For matched subjects: * Participant must be 40 to 75 years of age, inclusive. * Female participants who are postmenopausal or are post-bilateral surgical oophorectomy not linked to a history of cancer. Menopause is defined as being amenorrheic for at least 12 months without an alternative medical cause, with plasma FSH level \>30 IU/L or age ≥60 years. * Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination). * Body weight within the range 50 kg (40 kg for site in South Korea) to 100 kg and body mass index (BMI) within the range 18 to 36 kg/m2, inclusive. Exclusion Criteria: For participa…